E E Habib1, E S Fahmy. 1. Department of Clinical Oncology, Cairo University Faculty of Medicine, Cairo, Egypt, cairo.oncology@gmail.com.
Abstract
PURPOSE: The aim of this prospective, phase II clinical study is to evaluate the activity of gemcitabine and cisplatin in comparison to pemetrexed and carboplatin in patients with malignant pleural mesothelioma. PATIENTS AND METHODS: The patients were recruited from May 2008 to May 2011. One group included 21 cases who received cisplatin and gemcitabine. The other group included 19 cases who received pemetrexed and carboplatin. RESULTS: Response is superior in the pemetrexed group (p = 0.041). The median follow-up was 18 months (range 6-30 months). Cumulative survival at 1.5 years was 57.8 % for the pemetrexed carboplatin group. For the gemcitabine cisplatin group, the cumulative survival proportion at 1.5 years was 41 % (p = 0.0599). CONCLUSIONS:Pemetrexed plus carboplatin are a step forward in the treatment of mesothelioma, the prognosis for these patients remains poor. Cheaper combinations as gemcitabine and cisplatin may be considered sufficient to treat cases with advanced mesothelioma.
RCT Entities:
PURPOSE: The aim of this prospective, phase II clinical study is to evaluate the activity of gemcitabine and cisplatin in comparison to pemetrexed and carboplatin in patients with malignant pleural mesothelioma. PATIENTS AND METHODS: The patients were recruited from May 2008 to May 2011. One group included 21 cases who received cisplatin and gemcitabine. The other group included 19 cases who received pemetrexed and carboplatin. RESULTS: Response is superior in the pemetrexed group (p = 0.041). The median follow-up was 18 months (range 6-30 months). Cumulative survival at 1.5 years was 57.8 % for the pemetrexed carboplatin group. For the gemcitabine cisplatin group, the cumulative survival proportion at 1.5 years was 41 % (p = 0.0599). CONCLUSIONS:Pemetrexed plus carboplatin are a step forward in the treatment of mesothelioma, the prognosis for these patients remains poor. Cheaper combinations as gemcitabine and cisplatin may be considered sufficient to treat cases with advanced mesothelioma.
Authors: N J Vogelzang; M Goutsou; J M Corson; Y Suzuki; S Graziano; J Aisner; M R Cooper; K M Coughlin; M R Green Journal: Cancer Chemother Pharmacol Date: 1990 Impact factor: 3.333
Authors: M Z Wojtukiewicz; L R Zacharski; V A Memoli; W Kisiel; B J Kudryk; S M Rousseau; D C Stump Journal: Thromb Res Date: 1989-07-15 Impact factor: 3.944
Authors: Giovanni L Ceresoli; Paolo A Zucali; Adolfo G Favaretto; Francesco Grossi; Paolo Bidoli; Guido Del Conte; Anna Ceribelli; Alessandra Bearz; Emanuela Morenghi; Raffaele Cavina; Maurizio Marangolo; Hector J Soto Parra; Armando Santoro Journal: J Clin Oncol Date: 2006-03-20 Impact factor: 44.544
Authors: David J Sugarbaker; Michael T Jaklitsch; Raphael Bueno; William Richards; Jeanne Lukanich; Steven J Mentzer; Yolonda Colson; Phillip Linden; Michael Chang; Leah Capalbo; Elizabeth Oldread; Siyamek Neragi-Miandoab; Scott J Swanson; Lambros S Zellos Journal: J Thorac Cardiovasc Surg Date: 2004-07 Impact factor: 5.209
Authors: T Berghmans; M Paesmans; Y Lalami; I Louviaux; S Luce; C Mascaux; A P Meert; J P Sculier Journal: Lung Cancer Date: 2002-11 Impact factor: 5.705